valproate

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Epilepsy (label: complex partial seizures, simple and complex absence seizures, and adjunctive use in multiple...), Absence Seizures

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

US marketing discontinued: Drugs@FDA lists every US product of this approval as discontinued.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (30)
Absence Seizures
Epilepsy
NCT05722951 · Tanta University
2022-10-18 – 2024-06-20 · Epilepsy
What this study did
NCT01960075 · University of Virginia
2015-10 – 2019-05 · Benzodiazepine Refractory Status Epilepticus
What this study did
NCT01586208 · Hospital Universitari de Bellvitge
2010-01 – 2012-10 · Grand Mal Status Epilepticus, Non-convulsive Status Epilepticus
What this study did
NCT00236717 · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
1997-09 – 2000-11 · Epilepsy, Seizures
What this study did
Other / comorbidity
NCT06929273 · Bristol-Myers Squibb
2025-07-18 – 2028-06-13 · Bipolar Disorder Type I With Mania
What this study did
NCT05603104 · Dr. Inge Winter
2025-04-27 – 2026-06-24 · Schizophrenia and Related Disorders, Major Depressive Disorder, Bipolar Depression
What this study did
NCT06248931 · Kafrelsheikh University
2022-05-01 – 2024-06-30 · Migraine Disorders
What this study did
NCT03243461 · University of Göttingen
2018-07-17 – 2023-12-31 · Glioblastoma WHO Grade IV, Diffuse Midline Glioma Histone 3 K27M WHO Grade IV, Anaplastic Astrocytoma WHO Grade III, Diffuse Intrinsic Pontine Glioma, Gliomatosis Cerebri
What this study did
NCT04698525 · Universidad Autonoma de San Luis Potosí
2019-02-15 – 2020-01-15 · Migraine Headache
What this study did
NCT03039842 · National Cheng-Kung University Hospital
2013-01-01 – 2017-12-31 · Bipolar Disorder II
What this study did
NCT02374567 · Hannover Medical School
2015-01 – 2017-06-28 · Dementia, Depression, Schizophrenia, Psychosomatic Disorders, Anxiety Disorders
What this study did
NCT01671384 · All India Institute of Medical Sciences
2013-08 – 2016-12 · Spinal Muscular Atrophy
What this study did
NCT00681980 · University of Sao Paulo
2008-02 – 2015-12 · Paraparesis Spastic Tropical
What this study did
NCT01342549 · VA Office of Research and Development
2011-09 – 2015-06 · Alcohol Dependence
What this study did
NCT01750541 · Shahid Beheshti University of Medical Sciences
2012-12 – 2013-01 · Psychomotor Agitation
What this study did
NCT00665366 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2008-06 – 2011-10 · Bipolar Disorder Mania
What this study did
NCT00221403 · Children's Hospital Medical Center, Cincinnati
2004-09 – 2011-05 · Bipolar Disorder
What this study did
NCT00532818 · National Institute of Cancerología
2007-07 – 2010-12 · Metastatic Cervical Cancer
What this study did
NCT02456454 · Nationwide Children's Hospital
2006-01 – 2010-06 · Bipolar Disorder
What this study did
NCT00533299 · National Institute of Cancerología
2007-08 – 2009-12 · Ovarian Cancer
What this study did
NCT00071721 · Alzheimer's Disease Cooperative Study (ADCS)
2003-10 – 2009-12 · Alzheimer Disease
What this study did
NCT00266630 · Eli Lilly and Company
2005-11 – 2009-05 · Manic or Mixed Episode Associated With Bipolar I Disorder
What this study did
NCT00057681 · Washington University School of Medicine
2003-02 – 2008-12 · Bipolar Disorder
What this study did
NCT00447369 · Hospital Militar del General Luis Felipe Brieba Aran
2007-05 – 2008-03 · Migraine Disorders
What this study did
NCT00136110 · UMC Utrecht
2005-04 – 2007-02 · Amyotrophic Lateral Sclerosis
What this study did
NCT00254774 · AstraZeneca
2002-01 – 2006-03 · Bipolar Disorder
What this study did
NCT00065884 · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
— · Autism
What this study did
Phase 2/3 (5)
Other / comorbidity
NCT07166393 · Northwestern University
2027-05 – 2031-12 · Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain Injury
What this study did
NCT02265770 · Centre Leon Berard
2015-06-02 – 2031-08 · Childhood Ependymoma
What this study did
NCT05431595 · M.D. Anderson Cancer Center
2022-07-19 – 2027-02-02 · Delirium, Epileptics, Neuroleptics
What this study did
NCT02896270 · Universitair Ziekenhuis Brussel
2016-10 – 2019-12 · Idiopathic Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
What this study did
NCT00221637 · University Hospital, Bordeaux
2002-03 – 2005-07 · Neuralgia, Neuropathic Peripheral Pain
What this study did
Phase 2 (65)
Epilepsy
NCT03025906 · Xuanwu Hospital, Beijing
2017-02-16 – 2019-12 · Generalized Convulsive Status Epilepticus
What this study did
NCT00004758 · National Center for Research Resources (NCRR)
started 1993-11 · Spasms, Infantile, Epilepsy
What this study did
Other / comorbidity
NCT07831369 · Inova Health Care Services
2026-09-04 – 2030-12-30 · Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4
What this study did
NCT02068586 · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
2014-11-19 – 2027-12-31 · Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma, Stage IIB Intraocular Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIC Intraocular Melanoma, Stage I Uveal Melanoma AJCC V7, Stage II Uveal Melanoma AJCC V7, Stage III Uveal Melanoma AJCC V7
What this study did
NCT06714357 · National Cancer Institute, Naples
2025-03-12 – 2027-06-20 · Colorectal Cancer Metastatic
What this study did
NCT05821556 · National Cancer Institute, Naples
2023-06-12 – 2027-06 · Adenocarcinoma of the Pancreas
What this study did
NCT05694936 · Australasian Gastro-Intestinal Trials Group
2023-01-23 – 2027-06 · Metastatic Colorectal Cancer
What this study did
NCT07487675 · Tanta University
2024-09-29 – 2026-05-06 · Temporomandibular Joint Internal Derangement (ADWR)
What this study did
NCT04940572 · Centre d'Etude des Cellules Souches
2021-11-26 – 2025-12-01 · Wolfram Syndrome
What this study did
NCT04997811 · Prof. Janet Dunn
2021-12-21 – 2025-06-30 · Myelodysplastic Syndromes (MDS)
What this study did
NCT03357757 · AHS Cancer Control Alberta
2018-02-07 – 2025-03-31 · Cancer That is Associated With a Chronic Viral Infection, p16 Positive SCCHN, Squamous Cell Carcinoma of the Cervix, p16 Positive Squamous Cell Carcinoma of the Vagina or Vulva, p16 Positive Squamous Cell Carcinoma of the Penis, p16 Positive Squamous Cell Carcinoma of the Anus or Anal Canal, EBER Positive NPC, EBER Positive Hodgkins and Non-hodgkins Lymphona
What this study did
NCT03717909 · University of Birmingham
2018-12-28 – 2024-11-15 · Wolfram Syndrome
What this study did
NCT04310176 · National Cancer Institute, Naples
2019-05-24 – 2024-11 · Ras-mutated Metastatic Colorectal Cancer
What this study did
NCT06020898 · RenJi Hospital
2023-09-01 – 2024-04-30 · Acute Ischemic Stroke
What this study did
NCT02624128 · National Cancer Institute, Naples
2015-02-23 – 2023-12 · Squamous Cell Carcinoma of the Head and Neck
What this study did
NCT04531592 · Westat
2022-01 – 2023-06 · Acute Kidney Injury, Ischemia Reperfusion Injury
What this study did
NCT04531579 · Westat
2022-01 – 2023-06 · Acute Kidney Injury, Ischemia Reperfusion Injury
What this study did
NCT01817751 · Virginia Commonwealth University
2013-04-11 – 2023-05-12 · Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
What this study did
NCT02124174 · Patrick Stiff
2012-01 – 2022-01 · Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS
What this study did
NCT02848105 · Shanghai Jiao Tong University School of Medicine
2016-07 – 2019-12 · Peripheral Blood Stem Cell Transplantation, aGVHD
What this study did
NCT03204500 · El Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez
2016-05 – 2019-08 · Amyotrophic Lateral Sclerosis, Amyotrophic Lateral Sclerosis, Sporadic
What this study did
NCT01342692 · Assistance Publique - Hôpitaux de Paris
2011-06 – 2019-06 · MDS
What this study did
NCT03885154 · Kimberly S Jones
2017-10-03 – 2019-03-19 · Migraine in Children
What this study did
NCT02789813 · Prof. Dominique de Quervain, MD
2016-07 – 2018-06-30 · Phobia, Specific
What this study did
NCT01900730 · M.D. Anderson Cancer Center
2014-07-31 – 2018-06-01 · Breast Cancer
What this study did
NCT00879437 · Baylor College of Medicine
2009-09-01 – 2017-10-02 · Glial Cell Tumors, Malignant Gliomas, Glioblastoma Multiforme, Anaplastic Astrocytoma, Gliomatosis Cerebri, Gliosarcoma, Brainstem Glioma, Diffuse Intrinsic Pontine Glioma
What this study did
NCT01928849 · Duke University
2013-12 – 2017-09-26 · Pain, Phantom, Pain, Neuropathic
What this study did
NCT01730313 · Centers for Disease Control and Prevention
2016-02 – 2017-07 · Nodding Syndrome
What this study did
NCT02625779 · Ewha Womans University Mokdong Hospital
2016-03-01 – 2017-04-30 · Depression, Bipolar
What this study did
NCT01543139 · Ewha Womans University
2015-12-01 – 2017-04-30 · Bipolar Depression
What this study did
NCT03112889 · University College, London
2015-01 – 2017-04-05 · Glycogen Storage Disease Type V, McArdle Disease
What this study did
NCT01182285 · National Cancer Institute (NCI)
2010-09-24 – 2016-04-28 · Thyroid Neoplasm
What this study did
NCT00867672 · University Hospital Freiburg
2011-08 – 2016-02 · Acute Myeloid Leukemia
What this study did
NCT01233609 · Foundation Fighting Blindness
2010-11 – 2015-12 · Retinitis Pigmentosa
What this study did
NCT01399515 · Seoul National University Hospital
2011-03 – 2015-11 · Retinitis Pigmentosa, Retinal Diseases, Eye Diseases, Eye Disease, Hereditary, Retinal Degeneration
What this study did
NCT01333631 · Soroka University Medical Center
2011-06 – 2015-07 · Pancreatic Cancer
What this study did
NCT00414310 · M.D. Anderson Cancer Center
2006-12 – 2015-05 · Myelodysplastic Syndrome, Acute Myelogenous Leukemia
What this study did
NCT01695122 · Instituto do Cancer do Estado de São Paulo
2012-09 – 2014-11 · Head and Neck Cancer, Oral Cavity Cancer, Oropharyngeal Cancer
What this study did
NCT00302159 · National Cancer Institute (NCI)
2006-03 – 2014-11 · High Grade Gliomas, Brain Tumors
What this study did
NCT01619644 · University Hospital, Bordeaux
2012-04 – 2014-09 · Rubinstein-Taybi Syndrome
What this study did
NCT00759824 · European Lung Cancer Working Party
2008-09 – 2014-06 · Small Cell Lung Carcinoma
What this study did
NCT00289952 · Jean-Pierre Routy
2006-06 – 2012-12 · HIV Infections
What this study did
NCT00670046 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2008-05 – 2012-07 · Prostate Cancer
What this study did
NCT01548066 · Seoul National University Hospital
2011-09 – 2012-06 · Androgenetic Alopecia, Male Pattern Baldness
What this study did
NCT01016990 · Auxilio Mutuo Cancer Center
2009-08 – 2011-09 · Leukemia, Lymphoma
What this study did
NCT01010854 · University of California, San Francisco
2008-12-10 – 2011-07-29 · Breast Cancer
What this study did
NCT00524667 · CancerCare Manitoba
2008-01 – 2011-07 · Chronic Lymphocytic Leukemia
What this study did
NCT00481013 · University of Utah
2007-07 – 2010-11 · Spinal Muscular Atrophy
What this study did
NCT01011998 · New Mexico Cancer Research Alliance
2009-09 – 2010-07 · Chronic Myelogenous Leukemia
What this study did
NCT00439673 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2007-05 – 2010-07 · Myelodysplastic Syndromes
What this study did
Phase 1/2 (20)
Epilepsy
NCT04529954 · Cerebral Therapeutics LLC
2021-01-01 – 2024-03-01 · Focal Epilepsy
What this study did
NCT02899611 · Cerebral Therapeutics LLC
2016-08 – 2021-06-01 · Epilepsy
What this study did
Other / comorbidity
NCT03919292 · Virginia Commonwealth University
2019-05-01 – 2031-01-31 · Solid Tumor, Adult
What this study did
NCT06199557 · Haukeland University Hospital
2024-05-23 – 2029-09-30 · Acute Myeloid Leukemia, Adult, Myelodysplastic Syndromes, Adult
What this study did
NCT07226141 · Boston Children's Hospital
2026-07-01 – 2027-09-30 · Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
What this study did
NCT05920512 · Xue-chun Lu
2022-04-01 – 2025-04-01 · Hemophilia
What this study did
NCT01898104 · National Cancer Institute, Naples
2012-05 – 2024-04 · Colorectal Cancer
What this study did
NCT03825250 · University of Leicester
2018-11-06 – 2023-11-03 · Cardiac Valve Disease, Coronary Artery Disease, Organ Failure, Multiple
What this study did
NCT03525730 · Erasmus Medical Center
2018-04-18 – 2020-10-01 · HIV-1-infection
What this study did
NCT01369368 · University of Bergen
2013-08 – 2020-10 · Acute Myeloid Leukemia
What this study did
NCT01622439 · Lund University Hospital
2012-06 – 2018-03 · Diffuse Large B-cell Lymphoma
What this study did
NCT01203735 · Soroka University Medical Center
2011-02 – 2015-02 · Locally Advanced Inoperable Non-small-lung Cancer
What this study did
NCT00240110 · University of Miami
2006-03 – 2014-03 · Bipolar Disorder, Cocaine Dependence
What this study did
NCT00995332 · University of Bergen
2009-09 – 2013-06 · Acute Myelogenous Leukemia
What this study did
NCT01295593 · Cliniques universitaires Saint-Luc- Université Catholique de Louvain
2010-12 – 2013-04 · Chronic Lymphocytic Leukemia
What this study did
NCT00661453 · University of Utah
2008-04 – 2012-06 · Spinal Muscular Atrophy Type I
What this study did
NCT00605657 · Koneti Rao
2008-01 – 2011-09 · ALPS, Hypersplenism, Lymphadenopathy
What this study did
NCT00175812 · University of Bergen
2004-11 – 2009-11 · Acute Myelogenous Leukemia
What this study did
NCT00358319 · H. Lee Moffitt Cancer Center and Research Institute
2005-03 – 2007-04 · Malignant Melanoma
What this study did
NCT00075010 · M.D. Anderson Cancer Center
2004-01-23 – 2006-11-08 · Leukemia, Myelodysplastic Syndromes
What this study did
Phase 1 (46)
Epilepsy
NCT02027987 · Xijing Hospital
2013-10 – 2016-12 · Traumatic Brain Injury
What this study did
Other / comorbidity
NCT02446431 · Miller Children's & Women's Hospital Long Beach
2014-07 – 2029-07 · Solid Tumor
What this study did
NCT01552434 · M.D. Anderson Cancer Center
2012-10-16 – 2026-05-08 · Advanced Malignant Neoplasm, Castleman Disease, Digestive System Carcinoma, Erdheim-Chester Disease, Lip and Oral Cavity Carcinoma, Lymphangioleiomyomatosis, Malignant Endocrine Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Male Reproductive System Neoplasm, Malignant Neoplasm, Malignant Respiratory Tract Neoplasm, Malignant Thoracic Neoplasm, Malignant Urinary System Neoplasm, Mesothelial Neoplasm, Metastatic Malignant Neoplasm, Metastatic Urothelial Carcinoma, Neurofibromatosis Type 2, Recurrent Adult Soft Tissue Sarcoma, Recurrent Breast Carcinoma, Recurrent Childhood Soft Tissue Sarcoma, Recurrent Digestive System Carcinoma, Recurrent Female Reproductive System Carcinoma, Recurrent Male Reproductive System Carcinoma, Recurrent Malignant Neoplasm, Recurrent Pharyngeal Carcinoma, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Neoplasm, Soft Tissue Neoplasm, Stage III Breast Cancer AJCC v7, Stage III Pharyngeal Cancer, Stage IIIA Breast Cancer AJCC v7, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7, Stage IV Pharyngeal Cancer, Stage IVA Pharyngeal Cancer, Stage IVB Pharyngeal Cancer, Stage IVC Pharyngeal Cancer, Thyroid Gland Neoplasm
What this study did
NCT06729970 · Karuna Therapeutics, Inc., a Bristol Myers Squibb company
2024-12-26 – 2026-01-23 · Healthy Volunteers
What this study did
NCT06214130 · Desitin Arzneimittel GmbH
2023-09-22 – 2023-11-18 · Multiple Drug Use
What this study did
NCT06211283 · Desitin Arzneimittel GmbH
2023-09-11 – 2023-11-01 · Food-drug Interaction
What this study did
NCT05017454 · Kasr El Aini Hospital
2021-05-01 – 2023-04-01 · Alopecia Areata
What this study did
NCT05181007 · Haisco Pharmaceutical Group Co., Ltd.
2021-12-17 – 2022-06-01 · Drug Drug Interaction
What this study did
NCT03885947 · Alla Keyzner
2019-02-21 – 2021-03-10 · Hematological Malignancy, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Myelodysplastic Syndromes, Non-Hodgkin Lymphoma, Hodgkin Lymphoma
What this study did
NCT04482764 · Assiut University
2017-01-30 – 2018-12-30 · Breathhold
What this study did
NCT02520115 · Barbara Ann Karmanos Cancer Institute
2015-08 – 2018-11 · Adnexal Mass, Borderline Ovarian Epithelial Tumor, Ovarian Clear Cell Tumor, Ovarian Endometrioid Tumor, Ovarian Neoplasm, Ovarian Serous Tumor, Recurrent Ovarian Carcinoma
What this study did
NCT03903302 · Cereno Scientific AB
2017-10-06 – 2018-03-27 · Thrombosis
What this study did
NCT03385525 · Biogen
2017-09-12 – 2017-10-13 · Drug Interaction
What this study did
NCT02872428 · Dr. Hasan Alam
2016-11 – 2017-09-29 · Shock,Hemorrhagic, Trauma
What this study did
NCT01106872 · Mohammed M Milhem
2010-09 – 2017-08-22 · Sarcoma, Soft Tissue Sarcoma, Locally Advanced Sarcoma, Unresectable Sarcoma, Metastatic Sarcoma
What this study did
NCT02608736 · Barretos Cancer Hospital
2015-12 – 2017-07 · Head and Neck Squamous Cell Carcinoma
What this study did
NCT02761291 · Chang Gung Memorial Hospital
2016-05 – 2017-06 · Nasopharyngeal Carcinoma
What this study did
NCT02648633 · University of Virginia
2016-05-24 – 2017-02-21 · Glioblastoma
What this study did
NCT02144623 · Lund University Hospital
2015-01 – 2017-02-06 · Chronic Lymphocytic Leukemia
What this study did
NCT01951560 · Dr. Hasan Alam
2013-09 – 2016-05 · Shock,Hemorrhagic
What this study did
NCT01007695 · University of Utah
2010-05 – 2015-05 · Cancer
What this study did
NCT01729598 · Gregory Jicha, 323-5550
2012-04 – 2014-10 · Alzheimer's Disease
What this study did
NCT01738815 · State University of New York - Upstate Medical University
2011-12 – 2014-04 · Hematuria, Bladder Cancer
What this study did
NCT01010958 · Columbia University
2009-10 – 2014-02 · High Grade Sarcoma
What this study did
NCT01861990 · Medical University of South Carolina
2013-05 – 2013-12 · Pediatric Brain Tumor, Glioma, Anaplastic Astrocytoma, Medulloblastoma, Glioblastoma
What this study did
NCT00530907 · M.D. Anderson Cancer Center
2007-06 – 2013-11 · Advanced Cancer
What this study did
NCT01204450 · UNC Lineberger Comprehensive Cancer Center
2009-11 – 2013-03 · Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma, Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
NCT00084981 · National Cancer Institute (NCI)
2004-04 – 2013-02 · Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
What this study did
NCT00996060 · New Mexico Cancer Research Alliance
2008-07 – 2013-01 · Lung Cancer
What this study did
NCT00495872 · M.D. Anderson Cancer Center
2007-06 – 2012-10 · Solid Tumors
What this study did
NCT00529022 · M.D. Anderson Cancer Center
2007-08 – 2012-10 · Solid Tumors
What this study did
NCT00513162 · M.D. Anderson Cancer Center
2007-07 – 2012-09 · Neuroectodermal Tumor, Brain Metastases, Advanced Cancer
What this study did
NCT00107458 · Children's Oncology Group
2005-05 – 2012-03 · Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
What this study did
NCT01495104 · Hoffmann-La Roche
2011-10 – 2012-01 · Healthy Volunteer
What this study did
NCT00079378 · National Cancer Institute (NCI)
2004-02 – 2011-05 · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Untreated Adult Acute Myeloid Leukemia
What this study did
NCT01073059 · Chonbuk National University
started 2009-08 · Healthy
What this study did
NCT00312546 · University of North Carolina, Chapel Hill
2006-06 – 2009-10 · HIV Infections
What this study did
NCT00496444 · M.D. Anderson Cancer Center
2005-05 – 2009-10 · Advanced Cancers
What this study did
NCT00437957 · H. Lee Moffitt Cancer Center and Research Institute
2006-12 – 2009-04 · Brain Metastases
What this study did
NCT00109824 · National Cancer Institute (NCI)
2006-03 – 2009-03 · Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Mantle Cell Lymphoma
What this study did
NCT00563992 · New York State Psychiatric Institute
2001-01 – 2008-10 · Bipolar Disorder
What this study did
NCT00000629 · National Institute of Allergy and Infectious Diseases (NIAID)
— · HIV Infections
What this study did
NCT00246103 · H. Lee Moffitt Cancer Center and Research Institute
2004-03 – 2008-04 · Neoplasms, Advanced
What this study did
NCT00181220 · Johns Hopkins University
2004-04 – 2006-09 · Nasopharyngeal Carcinoma
What this study did
NCT00374075 · University of Utah
2003-09 – 2006-02 · Spinal Muscular Atrophy
What this study did
Phase 4 (38)
Epilepsy
NCT07046676 · The First Affiliated Hospital of University of South China
2022-12-01 – 2026-05-30 · Epilepsy
What this study did
NCT05881928 · Assiut University
2024-07-29 – 2025-04 · Epilepsy, Lamotrigine, Sodium Valproate Adverse Reaction
What this study did
NCT03689114 · Mario Negri Institute for Pharmacological Research
2021-05-10 – 2024-06-30 · Epilepsies, Partial
What this study did
NCT05641649 · Kathmandu University
2023-08-06 – 2023-11-30 · Epilepsy
What this study did
NCT05697614 · Dr Cipto Mangunkusumo General Hospital
2023-03-01 – 2023-06-30 · Drug Resistant Epilepsy
What this study did
NCT04967326 · Gia Dinh People Hospital
2016-01-01 – 2018-12-31 · Epilepsy
What this study did
NCT00807989 · Yonsei University
2008-03 – 2012-05 · Epilepsy
What this study did
NCT00713622 · Eisai Limited
2008-06 – 2009-04 · Epilepsy
What this study did
NCT01115959 · Wolfson Medical Center
2003-02 – 2008-12 · Post Cerebral Hemorrhage
What this study did
NCT00609245 · Vanderbilt University Medical Center
2007-12 – 2008-12 · Photosensitive Epilepsy
What this study did
NCT00385411 · Sanofi
2006-03 – 2008-10 · Epilepsy
What this study did
NCT00137709 · Chinese University of Hong Kong
2004-11 – 2008-07 · Epilepsy
What this study did
Other / comorbidity
NCT03048084 · Leiden University Medical Center
2018-02-01 – 2029-07-01 · Glioma
What this study did
NCT06081283 · University of North Carolina, Chapel Hill
2023-11-20 – 2025-01-22 · Brain Injuries, Acute, Brain Injuries, Traumatic, Brain Ischemia, Brain Hypoxia, Hypoxia-Ischemia, Brain, Heart Arrest, Stroke, Intracranial Hemorrhages, Coma, Persistent Vegetative State
What this study did
NCT06485726 · Kafrelsheikh University
2023-01-23 – 2024-07-05 · Migraine Disorders
What this study did
NCT06089356 · Tanta University
2023-01-01 – 2024-01-01 · Migraine
What this study did
NCT04513314 · University of Miami
2023-03-28 – 2023-03-28 · Covid19, Hyperactive Delirium, Pneumonia, Viral
What this study did
NCT04671589 · Mabaret Al-Asafara Hospitals
2021-06 – 2022-12 · Drug Toxicity
What this study did
NCT03652974 · Shanghai Mental Health Center
2018-09-06 – 2021-08-30 · Schizophrenia
What this study did
NCT03235531 · CAMC Health System
2017-07-11 – 2019-06-25 · Alcohol Dependence, Alcohol Withdrawal Syndrome, Trauma, Heavy Drinking, Alcohol Use Disorder
What this study did
NCT03914534 · Tecnoquimicas
2017-04-17 – 2019-02-12 · Healthy
What this study did
NCT02343575 · Stanford University
2015-01 – 2018-01 · Hyperactive Delirium, Mixed Delirium
What this study did
NCT02011750 · University of Pittsburgh
2013-04-01 – 2017-12-31 · Toxoplasmosis, Schizophrenia
What this study did
NCT01893229 · Guiyun Xu
2013-09 – 2015-12 · Bipolar Disorder
What this study did
NCT02870283 · Federal University of Rio Grande do Sul
2010-05 – 2015-09 · Bipolar Disorder
What this study did
NCT00794625 · Joseph Blader
2008-11 – 2013-04 · Attention Deficit Disorder With Hyperactivity
What this study did
NCT01267864 · Montefiore Medical Center
2010-11 – 2013-03 · Acute Migraine
What this study did
NCT01083784 · Samsung Medical Center
2010-03 – 2012-12 · Cardiac Arrest
What this study did
NCT00854581 · University of Miami
2007-11 – 2011-11 · Lymphoma, Precancerous/Nonmalignant Condition
What this study did
NCT00477373 · Sanofi
2006-12 – 2007-12 · Bipolar Disorder
What this study did
NCT00298857 · Northwell Health
2006-03 – 2007-03 · Healthy, Obesity, Pharmacokinetics
What this study did
NCT00194025 · University Hospitals Cleveland Medical Center
2004-11 – 2006-11 · Schizophrenia
What this study did
NCT00431522 · Sanofi
2004-12 – 2006-10 · Bipolar Disorder
What this study did
NCT00264173 · Sanofi
2004-02 – 2006-09 · Bipolar Disorder
What this study did
NCT00211250 · Joliet Center for Clinical Research
2005-07 – 2006-09 · Mood Disorder
What this study did
NCT00139074 · AstraZeneca
2005-07 – 2006-06 · Bipolar Disorder
What this study did
NCT00367874 · Sorlandet Hospital HF
2003-02 – 2003-11 · Opiate Dependence, Drug Dependence, Substance Withdrawal Syndrome
What this study did
NCT00153270 · Centre of Chinese Medicine, Georgia
2000-09 – 2001-04 · Bronchial Asthma
What this study did
Early phase / not applicable (16)
Epilepsy
NCT07052136 · RESnTEC, Institute of Research
2024-11-01 – 2025-04-30 · Status Epilepticus
What this study did
NCT01791868 · Assistance Publique - Hôpitaux de Paris
2013-02 – 2018-10 · Generalized Convulsive Status Epilepticus, Intensive Care Unit
What this study did
Other / comorbidity
NCT04486092 · National Cheng-Kung University Hospital
2015-02 – 2021-07 · Bipolar Disorder
What this study did
NCT02926976 · Shanghai Mental Health Center
2016-11 – 2019-09 · Schizophrenia
What this study did
NCT05830981 · Damanhour University
2015-01-01 – 2017-12-31 · Neurological Disorders
What this study did
NCT01463111 · Emory University
2011-05 – 2016-04 · Bipolar Disorder
What this study did
NCT00774306 · Thomas Jefferson University
2009-04 – 2012-06 · Subarachnoid Hemorrhage
What this study did
NCT01460563 · Seoul National University Bundang Hospital
2011-10 – 2011-12 · Cerebral Aneurysm
What this study did
NCT00810680 · All India Institute of Medical Sciences
2008-09 – 2009-03 · Chronic Lymphocytic Leukemia
What this study did
NCT00167934 · Washington University School of Medicine
2004-12 – 2008-12 · Schizophrenia
What this study did
NCT00570219 · University of Helsinki
2005-02 – 2008-05 · Substance Withdrawal Syndrome
What this study did
NCT00075777 · AIDS Malignancy Consortium
2005-02 – 2008-02 · Sarcoma
What this study did
NCT00519181 · University Hospital Pierre Zobda-Quitman
2006-03 – 2007-06 · HTLV-I-Associated Myelopathy
What this study did
NCT00203242 · Thomas Jefferson University
2003-07 – 2006-12 · Cluster Headache
What this study did
NCT00552500 · Washington University School of Medicine
2003-02 – 2005-12 · Insulin Resistance, Body Composition
What this study did
NCT00012558 · National Institute of Mental Health (NIMH)
1998-09 – 2005-09 · Bipolar Disorder
What this study did
Used as active comparator (5)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
Phase 2 (1)
Epilepsy
NCT02920060 · Banaras Hindu University
2015-01 – 2016-08 · Grand Mal Status Epilepticus
What this study did
Phase 4 (2)
Epilepsy
NCT03940326 · Mazandaran University of Medical Sciences
2018-04-01 – 2019-12-01 · Epilepsy, Idiopathic Generalized
What this study did
Other / comorbidity
NCT00976794 · University of Sao Paulo
2009-01 – 2012-06 · Bipolar I Disorder
What this study did
Early phase / not applicable (1)
Other / comorbidity
NCT00742638 · Shanghai Jiao Tong University School of Medicine
2008-03 – 2010-08 · Bipolar Disorder
What this study did
Appears in other studies (7)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (2)
Other / comorbidity
NCT01977300 · University of British Columbia
2003-01 – 2011-08 · Bipolar I Disorder
What this study did
NCT01188265 · National Cheng-Kung University Hospital
2007-06 – 2011-06 · Bipolar Disorder
What this study did
Phase 2 (1)
Other / comorbidity
NCT01674010 · OPKO Health, Inc.
2012-08 – 2014-06 · Bipolar 1 Disorder
What this study did
Phase 4 (4)
Other / comorbidity
NCT07047651 · Dr. Stavroula Rakitzi
2025-06-04 – 2027-12-20 · Treatment Resistant Schizophrenia, Treatment Resistant Bipolar Disorder
What this study did
NCT03161509 · Rambam Health Care Campus
2017-07-01 – 2019-01-01 · Bariatric Surgery Candidate
What this study did
NCT00484471 · Korea Otsuka International Asia Arab
2007-10 – 2012-11 · Bipolar Disorder
What this study did
NCT00261443 · Otsuka Pharmaceutical Development & Commercialization, Inc.
2005-09 – 2009-10 · Bipolar Disorder
What this study did

Competitive landscape

2 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Epilepsy: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Valproate: this drugApprovedSmall moleculeGABAergic neurotransmissionPartial signal
NCT00004817: Phase III NINDS trial (Temkin et al.): valproate did not reduce early or late post-traumatic seizure rates vs phenytoin control, and showed a trend toward higher mortality (13.4% vs 7.2%). missed
BrivaracetamApprovedSmall moleculeSynaptic vesicle glycoprotein 2A (SV2A)Partial signalNo reviewed efficacy summary in this indication
Cannabidiol (Epidiolex)ApprovedSmall moleculeGPR55 / TRPV1 / adenosine transport (multi-target), cannabinoidPartial signal
NCT02544763: Percent Change From Baseline in the Number of Tuberous Sclerosis Complex (TSC)-Associated Seizures During the Treatment Period (Maintenance and Titration) (Baseline; up to Week 16): GWP42003-P 25 mg/kg/Day -43.36 percent change (IQR -67.8 to -13.6) | GWP42003-P 50 mg/kg/Day -36.55 percent change (IQR -67 to -5.5) vs Placebo -20.08 percent change (IQR -47.1 to 3.1)
NCT02091375: Percentage Change From Baseline In Convulsive Seizure Frequency During The Treatment Period (Baseline to End of Treatment (EOT) (Day 99) or Early Termination (ET)): GWP42003-P 20 mg/kg/Day Dose -38.94 percent change (IQR -69.53 to -4.83) vs Placebo -13.29 percent change (IQR -52.53 to 20.2)
CarbamazepineApprovedSmall moleculeSodium channelsnot yet gradedNo reviewed efficacy summary in this indication
Cenobamate (Xcopri)ApprovedSmall moleculeSodium channels + GABA-A receptorsWeak signal
NCT03678753: USA and Rest of World (RoW): Percent Change in PGTC Seizure Frequency Per 28 Days During the Double-blind Treatment Period Relative to Baseline. (Baseline and 22-week Double-blind Treatment Period.): Cenobamate -71.9% (range -100 to 273) vs Placebo -39.61% (range -100 to 211.8)
NCT04557085: Median percent change in 28-day focal seizure frequency, 6-week maintenance phase: placebo -25.9% vs cenobamate 100 mg -42.6%, 200 mg -78.3%, 400 mg -100% (all p<.001; Epilepsia 2026)
Clobazam (Onfi)ApprovedSmall moleculeGABA-A receptorReliable signal
NCT00518713: Percent Reduction in Number of Drop Seizures (12-week Maintenance Period). (4-week baseline period and 12-week maintenance period): Clobazam Low Dose 41.2 Percent Reduction (range -119 to 100) | Clobazam Medium Dose 49.4 Percent Reduction (range -262 to 100) | Clobazam High Dose 68.3 Percent Reduction (range -39 to 100) vs Placebo 12.1 Percent Reduction (range -374 to 100)
NCT01160770: Median Percent Reduction in Average Weekly Rate of Drop Seizures Based on the 7-day Assessment (Baseline to month 36): Clobazam 92.3 percentage of drop seizures (range -588 to 100)
Clobazam (Sympazan)ApprovedSmall moleculeGABA-A receptor (benzodiazepine site)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Diastat)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valium)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Diazepam (Valtoco)ApprovedSmall moleculeGABA-A receptorWeak signalFeatured results are non-efficacy only in this race
Divalproex Sodium (Depakote ER)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Divalproex Sodium (Depakote)ApprovedSmall moleculeGABAergic neurotransmissionnot yet gradedNo reviewed efficacy summary in this indication
Eslicarbazepine Acetate (Aptiom)ApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT02484001: Primary endpoint (retention time / probability of ESL withdrawal) at 24 months: 0.0638 (95% CI 0.0292-0.1366) in the ESL/ESL group vs 0.0472 (95% CI 0.0180-0.1210) in the CBZ-CR/ESL group
NCT00988156: Change From Baseline in Seizure Frequency (Baseline up to Visit 7): Esl (BIA 2-093) 36.6 seizures/month (Standard Deviation 72.47) vs Placebo 62 seizures/month (Standard Deviation 186.19) missed
EthosuximideApprovedSmall moleculeT-type calcium channelReliable signal
NCT00088452: Freedom from treatment failure at 16–20 weeks: 81/154 ethosuximide vs 43/146 lamotrigine, odds ratio 2.66 (95% CI 1.65–4.28; p<0.001); ethosuximide vs valproic acid: 81/154 vs 85/146, with no direct statistical comparison posted.
EverolimusApprovedSmall moleculemTOR kinase, mTOR (mTORC1) (inhibitor)Reliable signal
NCT01713946: Primary 1, response rate (≥50% seizure-frequency reduction) in the maintenance period: placebo 15.1%, low-exposure everolimus 28.2% (p=0.0077), high-exposure everolimus 40.0% (p<0.0001), met for both doses. Primary 2, median percentage reduction in seizure frequency: placebo 14.9%, low exposure 29.3% (p=0.0028), high exposure 39.6% (p<0.0001), met for both doses.
FelbamateApprovedSmall moleculeNMDA receptor (glycine site, antagonist)not yet gradedNo reviewed efficacy summary in this indication
Fenfluramine (Fintepla)ApprovedSmall moleculeSerotonin 5-HT2 receptorsReliable signal
NCT02682927: Change From Baseline in the Mean Convulsive Seizures Frequency (MCSF) to the Combined Titration and Maintenance Periods (T+M) in Participants Receiving ZX008 0.8 mg/kg/Day Compared to Placebo (From Baseline up to 14 weeks [Titration Period (2 weeks) plus Maintenance Period (12 weeks)]): Study 1: ZX008 0.8 mg/kg/Day -13.11 seizure frequency per 28 days (Standard Deviation 25.5) | Study 3: ZX008 0.8 mg/kg/Day -3.54 seizure frequency per 28 days (Standard Deviation 124.132) vs Study 1: Placebo -6.71 seizure frequency per 28 days (Standard Deviation 24.263) | Study 3: Placebo 1.54 seizure frequency per 28 days (Standard Deviation 21.966)
FosphenytoinApprovedSmall moleculeVoltage-gated sodium channelPartial signalNo reviewed efficacy summary in this indication
GabapentinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsPartial signal
NCT00007670: VA Cooperative Study 428 (18 centers, 593 elderly patients with new-onset seizures), matching this trial's title/sponsor/design exactly. Primary endpoint (12-month trial retention): early-termination rates were gabapentin 51%, lamotrigine 44.2%, carbamazepine 64.5% (p=0.0002); gabapentin significantly outperformed carbamazepine (p=0.008) but was not shown superior to lamotrigine. Seizure control was similar across all three arms.
NCT00603473: Response Ratio of Gabapentin in Japanese Pediatric Patients With Partial Seizures (12 weeks): Gabapentin -0.158 ratio (95% CI -0.221 to -0.096)
GanaxoloneApprovedSmall moleculeGABA-A receptorPartial signal
NCT04391569: Percentage of Participants With SE Cessation Within 30 Minutes of Investigational Product (IP) Initiation Without Medications for the Acute Treatment of SE (Up to 30 minutes): Ganaxolone 79.59% (95% CI 65.657 to 89.755) vs Placebo 12.77% (95% CI 4.832 to 25.741)
NCT01963208: Double Blind: Cohort 2: Percent Change From Baseline in 28-day Seizure Frequency During Titration + Maintenance Period (Baseline and Week 14): Double Blind: Cohort 2 - Ganaxolone -21.28 Percent change (95% CI -29.6 to -14.29) | Double Blind: Cohort 2 - Placebo -10.25 Percent change (95% CI -20.14 to -1.28) missed
Lacosamide (Vimpat)ApprovedSmall moleculeVoltage-gated sodium channelsReliable signal
NCT00136019: Median % reduction in seizure frequency/28 days: lacosamide 400mg/day -37.3% (p=0.008), 600mg/day -37.8% (p=0.006), vs placebo -20.8%; >=50% responder rates 38.3% (400mg) and 41.2% (600mg) vs 18.3% placebo (p<0.001).
NCT02408523: Primary endpoint, time to second PGTC seizure over 24 weeks: hazard ratio 0.540 (95% CI 0.377 to 0.774), p<0.001, lacosamide vs placebo (CT.gov posted results; 49 vs 76 patients with a second PGTC seizure).
LamotrigineApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00088452: Number of Participants With Freedom From Treatment Failure at 16-20 Weeks of Double Blind Therapy (First 16-20 weeks of double blind therapy): Ethosuximide 81/154 | Lamotrigine 43/146 vs Valproic Acid 85/146 missed
NCT01431976: Number of Participants Who Were Seizure Free as Confirmed by Hyperventilation (HV)-Electroencephalography (EEG) at the End of the Maintenance Phase (MP) (Week 12 of the Maintenance Phase (up to Study Week 50)): Lamotrigine 7/20
Levetiracetam (Elepsia XR)
ApprovedUS marketing discontinued
Small moleculeSynaptic vesicle glycoprotein 2A (SV2A)not yet gradedNo reviewed efficacy summary in this indication
Levetiracetam (Keppra XR)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signalFeatured results are non-efficacy only in this race
Levetiracetam (Keppra)ApprovedSmall moleculeSynaptic vesicle protein 2A (SV2A)Partial signal
NCT00150709: Percentage Change From Baseline in Partial Onset (Type I) Seizure Frequency Per Week Over Time During the Treatment Period (During the Treatment Period (an average of 2 years), compared to Baseline): N159 PBO/LEV -66.4 percentage of change (IQR -90 to -22.3) | N159 LEV/LEV -47.8 percentage of change (IQR -76.2 to -25.4) | N01010+N151 LEV/LEV -66.4 percentage of change (IQR -93.6 to -5.6)
NCT00615615: Partial-onset seizure frequency per week during the 14-week treatment period (primary endpoint): 26.8% greater reduction with levetiracetam vs placebo (p=0.0002, 95% CI 14.0-37.6%); 50%-responder rate 44.6% (45/101) LEV vs 19.6% (19/97) placebo (p=0.0002).
LorazepamApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
Midazolam (Nayzilam)ApprovedSmall moleculeGABA-A receptor, GABA-A receptor (benzodiazepine site)Reliable signal
NCT01390220: Participants Who Met the Criteria for Treatment Success After Administration of the Double-blind Dose in the Comparative Phase (CP) (6 hours): USL261 CP 72/134 vs Placebo CP 23/67
NCT01999777: Number of Participants That Were Seizure-free (6 hours): USL261 17/31 vs Placebo 12/31 missed
Oxcarbazepine (Oxtellar XR)ApprovedSmall moleculeVoltage-gated sodium channelPartial signalFeatured results are non-efficacy only in this race
Oxcarbazepine (Trileptal)ApprovedSmall moleculeVoltage-gated sodium channelWeak signal
NCT00050934: Median absolute change in type 1 (partial) seizure frequency per 24 hours: -2.00 (high-dose oxcarbazepine, 60 mg/kg/day) vs -1.37 (low-dose, 10 mg/kg/day), p=0.043; median percentage reduction 83.33% (high-dose) vs 46.18% (low-dose), p=0.047.
Perampanel (Fycompa)ApprovedSmall moleculeAMPA receptor (antagonist)Weak signal
NCT01393743: Core study: median percent change in PGTC seizure frequency per 28 days, perampanel -76.5% vs placebo -38.4%, median difference -30.8 (95% CI -45.5 to -15.2), p=0.0001; 50% responder rate in maintenance 64.2% vs 39.5%, p=0.0019 (n=81 each) (CT.gov posted results).
NCT00699582: Median percent change in 28-day seizure frequency: placebo -9.7%, perampanel 8 mg -30.5% (p<0.001), 12 mg -17.6% (p=0.011); 50% responder rate 14.7%, 33.3% (p=0.002) and 33.9% (p<0.001) (Study 305, Epilepsia 2013).
Phenobarbital Sodium Injection (Sezaby)ApprovedSmall moleculeGABA-A receptornot yet gradedNo reviewed efficacy summary in this indication
PhenytoinApprovedSmall moleculeVoltage-gated sodium channelsnot yet gradedNo reviewed efficacy summary in this indication
PregabalinApprovedSmall moleculeα2δ subunit of voltage-gated calcium channelsWeak signal
NCT01747915: Log-transformed (Log) 28-day Seizure Rate for All Primary Generalized Tonic-Clonic (PGTC) Seizures During 12-Week Double-Blind Treatment Phase (Day 1 up to Week 12): Pregabalin 5 mg/kg/Day or 7 mg/kg/Day or 300 mg/Day 1.17 Seizure per 28 days (Standard Error 0.097) | Pregabalin 10 mg/kg/Day or 14 mg/kg/Day or 600 mg/Day 1.13 Seizure per 28 days (Standard Error 0.095) vs Placebo 1.14 Seizure per 28 days (Standard Error 0.098) missed
PrimidoneApprovedSmall molecule—not yet gradedNo reviewed efficacy summary in this indication
Repository Corticotropin (Acthar Gel)ApprovedPeptideMelanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist)not yet gradedNo reviewed efficacy summary in this indication
RufinamideApprovedSmall moleculeVoltage-gated sodium channelPartial signal
NCT00334958: Primary endpoint, median percentage reduction in total partial seizure frequency per 28 days (maintenance phase vs baseline, ITT): rufinamide 23.25% vs placebo 9.80%, p = 0.007 (Biton et al., Epilepsia 2011; CT.gov posts the same medians with no statistical analysis).
StiripentolApprovedSmall moleculeGABA-A receptorWeak signalNo reviewed efficacy summary in this indication
TiagabineApprovedSmall moleculeGABA transporter (uptake carrier)not yet gradedNo reviewed efficacy summary in this indication
Topiramate (Eprontia)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Qudexy XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydraseReliable signal
NCT01142193: Percent Reduction From Baseline in Weekly (7 Day) Partial-onset Seizure Frequency During the Titration Plus Maintenance Phase Compared to Baseline. (11 weeks): USL255 39.5 Percent Reduction (range -227.3 to 100) | Placebo 21.65 Percent Reduction (range -531.2 to 100)
Topiramate (Topamax Sprinkle)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Topiramate (Topamax)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasePartial signal
NCT00113815: Primary endpoint, median % reduction from baseline in daily partial-onset-seizure rate (video-EEG): topiramate 25 mg/kg 20.4% vs placebo 13.1% (p=0.97); 15 mg/kg dose p=0.97 vs placebo; 5 mg/kg dose p=0.91 vs placebo -- no dose significantly better than placebo. missed
NCT00236756: Topiramate add-on in Lennox-Gastaut syndrome: median percentage reduction from baseline in average monthly seizure rate 14.8% with topiramate versus a -5.1% increase with placebo; a >=50% reduction from baseline in major seizures (drop attacks and tonic-clonic seizures) was reached by 33% of the topiramate group versus 8% of the control group.
Topiramate (Trokendi XR)ApprovedSmall moleculeVoltage-gated sodium channels; GABA-A receptor; AMPA/kainate glutamate receptors; carbonic anhydrasenot yet gradedNo reviewed efficacy summary in this indication
Vigabatrin (Sabril)ApprovedSmall moleculeGABA transaminase (GABA-T)Partial signal
NCT02849457: Cognitive Assessment Scores and Developmental Impact (24 months): Delayed Vigabatrin (Placebo) 83.9 score on a scale ± 17.3 vs Early Vigabatrin 80.9 score on a scale ± 15.6 vs Watchful Waiting (Control Group) 97.3 score on a scale ± 16.9 vs Watchful Waiting (Open Label Vigabatrin) 85.0 score on a scale ± 21.6; p=0.8681 (Delayed Vigabatrin (Placebo) vs Early Vigabatrin) missed
Vigabatrin (Vigafyde)ApprovedSmall moleculeGABA transaminase (GABA-T)not yet gradedNo reviewed efficacy summary in this indication
Zonisamide (Zonegran)ApprovedSmall moleculeVoltage-gated sodium channelsWeak signalFeatured results are non-efficacy only in this race
Zonisamide (Zonisade)ApprovedSmall moleculeVoltage-gated sodium and T-type calcium channelsnot yet gradedNo reviewed efficacy summary in this indication
AzetukalnerPhase 3Small moleculeKv7 potassium channelReliable signal
NCT05614063: Median % reduction in monthly focal seizure frequency at Week 12 (X-TOLE2, double-blind period): 25 mg dose -53.2% vs placebo -10.4%; 15 mg dose -34.5% vs placebo -10.4%
BexicaserinPhase 3Small moleculeSerotonin 5-HT2C receptor (agonist)Partial signal
NCT05364021: Primary endpoint, median percentage change in countable motor seizures over the treatment period: bexicaserin -59.8% (n=35) vs placebo -17.4% (n=9), difference 42.4%, p = .0538 (not statistically significant) (PACIFIC, Epilepsia 2026). missed
CarisbamatePhase 3Small moleculeVoltage-gated sodium channelPartial signal
NCT00425282: Primary endpoint, median percent reduction in partial-onset seizure frequency (double-blind phase vs baseline, ITT): carisbamate 400 mg/day 27.27% (n=191) vs placebo 15.21% (n=183), P = 0.009; carisbamate 200 mg/day 16.44% (n=187), P = 0.678 vs placebo (pre-specified Wilcoxon rank sum tests, EU Clinical Trials Register results).
NCT00433667: Primary endpoint, responder rate (at least 50% reduction in partial-onset seizure frequency, double-blind phase vs baseline): carisbamate 400 mg 23.8% and 200 mg 23.1% vs placebo 21.3%; difference 2.48 points (95% CI -6.04 to 11), P = 0.553 (400 mg) and 1.84 points (95% CI -6.58 to 10.26), P = 0.637 (200 mg) (pre-specified CMH tests, EU Clinical Trials Register results). missed
Clemizole (EPX-100)Phase 3Small moleculeHistamine H1 receptor, Serotonin receptors (5-HT)not yet gradedNo reviewed efficacy summary in this indication
Diazepam (Libervant)Phase 3Small moleculeGABA-A receptorWeak signalFeatured results are safety only in this race
ElsunersenPhase 3RNA / oligonucleotideSCN2A (antisense knockdown)Partial signal
NCT05737784: Part A (randomized 3:1, sham-controlled, 9 patients): 77% placebo-adjusted seizure reduction from baseline (p=0.015) (Praxis, 2026-04-06).
RAP-219Phase 3Small moleculeAMPA receptor (TARP γ8-dependent)Weak signal
NCT06377930: Primary endpoint met: 85.2% of patients achieved ≥30% reduction in long episodes (LEs) from baseline (p<0.0001); 72.0% achieved ≥50% reduction in clinical seizures (p<0.0001)
RelutriginePhase 3Small moleculeVoltage-gated sodium channel (persistent current)not yet gradedNo reviewed efficacy summary in this indication
Staccato AlprazolamPhase 3Small moleculeGABA-A receptorReliable signal
NCT03478982: 1.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8); 2.0 mg: 65.8% vs 42.5% placebo (difference 23.3 percentage points; p=0.0392; 95% CI 1.8 to 44.8)
VormatriginePhase 3Small moleculeVoltage-gated sodium channel (NaV1.2 / NaV1.6)Partial signal
NCT06999902: Primary success measure (reduction in focal seizure frequency over 12 weeks versus placebo) not met, per Praxis; the secondary 50% responder rate was met. The company disclosed no numbers. missed
YCJ-01Phase 3BotanicalCannabinoids (full-spectrum cannabis extract)not yet gradedNo reviewed efficacy summary in this indication
Cannabidiol (JZP926)Phase 2/3Small moleculeCannabidiol (CBD) modulates multiple targets, including the transient receptor potential vanilloid 1 (TRPV1) and the orphan G-protein-coupled receptor GPR55, cannabinoidnot yet gradedNo reviewed efficacy summary in this indication
OpakalimPhase 2/3Small moleculeKv7 potassium channelWeak signal
NCT06425159: Closed early with 27 subjects: median time to second generalized tonic-clonic seizure 141 days with opakalim vs 47 days with placebo; no formal statistical test reported (Biohaven, 2026-05-26).
ABS-1230Phase 2Small moleculeKCNT1 (KNa1.1/Slack) channelnot yet gradedNo reviewed efficacy summary in this indication
AV078Phase 2Small moleculemTORC1 (mammalian target of rapamycin complex 1) (inhibitor)not yet gradedNo reviewed efficacy summary in this indication
BMB-101Phase 2Small moleculeSerotonin 5-HT2C receptor (biased agonist)not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 62 furthest-along competitors are listed; 11 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow valproate to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Colorectal Cancer MetastaticRecruiting
Est. primary completion 2026-12-20 · NCT06714357 · CT.gov ↗
What to watch
2027 (4)
February 2027 (1)
Phase 2/3Delirium, Epileptics, NeurolepticsActive not recruiting
Est. primary completion 2027-02-02 · NCT05431595 · CT.gov ↗
What to watch
September 2027 (2)
Phase 1/2Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia StrabismicRecruiting
Est. primary completion 2027-09-30 · NCT07226141 · CT.gov ↗
What to watch
Phase 2Glioblastoma, Astrocytoma, IDH-Mutant, Grade 4Recruiting
Est. primary completion 2027-09-30 · NCT07831369 · CT.gov ↗
What to watch
December 2027 (1)
Phase 2Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma …Active not recruiting
Est. primary completion 2027-12-31 · NCT02068586 · CT.gov ↗
What to watch
2028 (4)
January 2028 (1)
Phase 4GliomaRecruiting
Est. primary completion 2028-01-01 · NCT03048084 · CT.gov ↗
What to watch
June 2028 (3)
Phase 2/3Childhood EpendymomaRecruiting
Est. primary completion 2028-06 · NCT02265770 · CT.gov ↗
What to watch
Phase 3Bipolar Disorder Type I With ManiaRecruiting
Est. primary completion 2028-06-13 · NCT06929273 · CT.gov ↗
What to watch
Phase 3Bipolar DepressionRecruiting
Est. primary completion 2028-06-30 · NCT05973786 · CT.gov ↗
What to watch
2031 (1)
May 2031 (1)
Phase 2/3Moderate Traumatic Brain Injury (TBI), Severe Traumatic Brain InjuryNot yet recruiting
Est. primary completion 2031-05 · NCT07166393 · CT.gov ↗
What to watch

See the full readout calendar ↗